Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27798996 | 0.97 | TDP1 (0.50) | TDP1 | |
| N,N-Dimethylethanaminium SCHEMBL2146563 | 0.80 | TDP1 (0.53) | TDP1 | |
| Bromoethane SCHEMBL11526729 | 0.79 | TDP1 (0.61) | TDP1 | |
| Isobutane SCHEMBL28239716 | 0.78 | CHRM2 (0.36) | — | |
| SCHEMBL9376579 | 0.75 | — | — | |
| SCHEMBL28021736 | 0.74 | TDP1 (0.67) | TDP1 | |
| SCHEMBL11058310 | 0.73 | TDP1 (0.53) | TDP1 | |
| SCHEMBL2020 | 0.73 | — | — | |
| SCHEMBL124190 | 0.73 | — | — | |
| SCHEMBL30 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140983-A1 | SINGLE STRANDED DNA ENZYME INHIBITORS | MASSEY UNIVERSITY (NZ) | 2024-05-02 | — | — | US | disclosed |
| CN-110248969-A | Method for continuous synthesis of modified diene elastomers using lithium amide initiators | 米其林集团总公司 | 2019-09-17 | — | — | CN | disclosed |
| US-20180155270-A1 | PROCESS FOR PREPARATION OF CINACALCET INTERMEDIATE AND CINACALCET HYDROCHLORIDE | LUPIN LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
| EP-3143015-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD Pharmaceuticals, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| WO-2016193882-A1 | PROCESS FOR PREPARATION OF CINACALCET INTERMEDIATE AND CINACALCET HYDROCHLORIDE | LUPIN LIMITED (IN) | 2016-12-08 | — | — | WO | disclosed |
| CN-105272829-A | Synthetic method for 2,6-dichlorophenol | LIANYUNGANG ZHICHENG CHEMICAL CO LTD | 2016-01-27 | — | — | CN | disclosed |
| WO-2015175632-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| US-9006271-B2 | 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanomethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as NK1 receptor antagonists | NERRE THERAPEUTICS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-20140249188-A1 | 5-[5-[2-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-2-METHYLPROPANOMETHYLPROPANOYLMETHYLAMINO]-4-(4-FLUORO-2-METHYLPHENYL)]-2-PYRIDINYL-2-ALKYL-PROLINAMIDE AS NK1 RECEPTOR ANTAGONISTS | NERRE THERAPEUTICS LIMITED (GB) | 2014-09-04 | — | — | US | disclosed |
| US-8822504-B2 | 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanomethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as NK1 receptor antagonists | NERRE THERAPEUTICS LIMITED (GB) | 2014-09-02 | — | — | US | disclosed |
| US-20110060015-A1 | 5-[5-[2-(3,5-BIS(Trifluoromethyl)Phenyl)-2-MethylpropanoMethylpropanoylmethylamino]-4-(4-Fluoro-2-Methylphenyl)]-2-Pyridinyl-2-Alkyl-Prolinamide As NK1 Receptor Antagonists | NERRE THERAPEUTICS LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| WO-2009138393-A1 | 5-[5-[2-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-2-METHYLPROPANOYLMETHYLAMINO]-4-(4-FLUORO-2-METHYLPHENYL)]-2-PYRIDINYL-2-ALKYL-PROLINAMIDE AS NK1 RECEPTOR ANTAGONISTS | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2009-11-19 | — | — | WO | disclosed |
| US-20090286836-A1 | Novel Compounds | NERRE THERAPEUTICS LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-7482358-B2 | Imidazoline compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20060135559-A1 | Novel imidazoline compounds | MSD K.K. (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1264826-B1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMA CO LTD (JP) | 2005-03-30 | — | — | EP | disclosed |
| EP-1264826-A1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
| US-5231184-A | Viricide intermediate | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-07-27 | — | — | US | disclosed |
| EP-0056154-B1 | PROCESS FOR THE PREPARATION OF 2,2-DIMETHYL-3-VINYL-CYCLOPROPANE-CARBOXYLIC ACIDS AND THEIR ESTERS | BAYER AG (DE) | 1984-05-23 | — | — | EP | disclosed |
| EP-0056154-A1 | Process for the preparation of 2,2-dimethyl-3-vinyl-cyclopropane-carboxylic acids and their esters | BAYER AG (DE) | 1982-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135559-A1 | Novel imidazoline compounds | GPR119, NPY1R, NPY2R | TDP1 1823/4885 |
| US-20180155270-A1 | PROCESS FOR PREPARATION OF CINACALCET INTERMEDIATE AND CINACALCET HYDROCHLORIDE | SI, ACSL4, C9 | TDP1 4497/4885 |
| US-20090286836-A1 | Novel Compounds | MRGPRX1, MRGPRX2, MRGPRX4 | TDP1 4222/4885 |
| US-20240140983-A1 | SINGLE STRANDED DNA ENZYME INHIBITORS | APOBEC3A, APOBEC3C, APOBEC3G | TDP1 29/4885 |
| US-20110060015-A1 | 5-[5-[2-(3,5-BIS(Trifluoromethyl)Phenyl)-2-MethylpropanoMethylpropanoylmethylamino]-4-(4-Fluoro-2-Methylphenyl)]-2-Pyridinyl-2-Alkyl-Prolinamide As NK1 Receptor Antagonists | TACR1, BDKRB2, TACR2 | TDP1 3988/4885 |
| US-20140249188-A1 | 5-[5-[2-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-2-METHYLPROPANOMETHYLPROPANOYLMETHYLAMINO]-4-(4-FLUORO-2-METHYLPHENYL)]-2-PYRIDINYL-2-ALKYL-PROLINAMIDE AS NK1 RECEPTOR ANTAGONISTS | TACR1, BDKRB2, TACR2 | TDP1 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.